国际肺癌研究协会分期项目:肺神经内分泌癌分期修订数据库及第九版TNM分类提案
该研究基于2011年1月至2019年12月诊断的肺高级别神经内分泌癌(包括纯小细胞癌、复合小细胞癌和大细胞神经内分泌癌)数据,验证第九版肺癌TNM分类新亚分类(N2a、N2b、M1c1、M1c2)的适用性。小细胞癌数据验证了第九版分类,大细胞神经内分泌癌数据不足以完成生存分析但显示生存随分期增加而下降。结论认为第九版TNM分类适用于神经内分泌癌患者,是临床实践的合适标准。
要点
- 小细胞癌数据验证了第九版肺癌TNM分类,包括N2a、N2b及M1c1、M1c2亚分类。
- 大细胞神经内分泌癌数据不足以完成生存分析,但现有数据显示生存随临床和病理分期增加而下降。
- 第九版TNM分类适用于神经内分泌癌患者,是临床实践的合适标准。
核心结论
- 第九版TNM分类适用于神经内分泌癌患者,是临床实践的合适标准。
研究设计与样本
- 数据库纳入2011年1月至2019年12月诊断的神经内分泌癌病例,分为纯小细胞癌、复合小细胞癌伴非小细胞肺癌和大细胞神经内分泌癌。
- 共有6181例纯和复合小细胞癌及697例大细胞神经内分泌癌病例可用。
- 小细胞癌生存分析包括4453例临床分期和583例病理分期数据;大细胞神经内分泌癌相应为585例和508例。
- 生存采用Kaplan-Meier法计算,组间比较采用log-rank检验,预后分组采用Cox回归分析。
主要发现
- 小细胞癌数据验证了第九版肺癌分类,包括新亚分类N2a(单站同侧纵隔或隆突下淋巴结受累)和N2b(多站同侧或隆突下淋巴结受累)。
- 小细胞癌数据还验证了M1c亚分类为M1c1(单个胸外器官系统多发病灶)和M1c2(多个胸外器官系统受累)。
- 大细胞神经内分泌癌数据不足以完成生存分析,但现有数据显示生存随临床和病理分期增加而下降。
关键数值与推荐
- 小细胞癌生存分析纳入4453例临床分期和583例病理分期病例;大细胞神经内分泌癌纳入585例临床分期和508例病理分期病例。
临床怎么用
- 第九版TNM分类适用于神经内分泌癌患者,是临床实践的合适标准。
局限性
- 大细胞神经内分泌癌数据不足以完成完整的生存分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Pulmonary high-grade neuroendocrine carcinoma (NEC) includes SCLC and large cell NEC (LCNEC). The seventh and eighth editions of the TNM classification for lung cancer confirmed the applicability of this staging system for SCLC. With the proposal of N2 and M1c subcategories for the ninth edition classification, we assessed the applicability to NECs. METHODS: The database included NEC cases diagnosed between January 2011 and December 2019. Eligible cases, with valid survival time and eighth edition TNM stage, were classified as pure SCLC, combined SCLC with NSCLC, and LCNEC. Survival was calculated using the Kaplan-Meier method, pairwise differences using a log-rank test, and prognostic groups using a Cox regression analysis. RESULTS: There were 6181 pure and combined SCLC and 697 LCNEC cases available. For SCLC, survival outcome analyses included 4453 cases with clinical stage and 583 with pathologic stage data. The corresponding numbers for LCNEC were 585 and 508. The SCLC data validated the ninth edition classification for lung cancer, including the proposed new subcategories, N2a, single-station ipsilateral mediastinal or subcarinal lymph node involvement, and N2b, involvement of multiple ipsilateral or subcarinal stations. The data also validated the subcategorization of M1c into M1c1 (multiple lesions in a single extrathoracic organ system) and M1c2 (involvement of multiple extrathoracic organ systems). The LCNEC data were insufficient for complete survival analysis, but the available data reported decreasing survival with increasing clinical and pathologic stages. CONCLUSIONS: The ninth edition TNM classification applies to patients with NEC and is the appropriate standard for use in clinical practice.
引用
- Tsao MS, Rosenthal A, Nicholson AG, et al. The International Association for the Study of Lung Cancer Staging Project: The Database and Proposal for the Revision of the Staging of Pulmonary Neuroendocrine Carcinoma in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2025. PMID: 39864546. doi:10.1016/j.jtho.2025.01.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。